Dipeptidyl-Peptidase-4 Inhibitors Shown Not to Increase Short-Term Risk of Pancreatic Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Diabetes, Obesity and Metabolism, researchers at the University of North Carolina Gillings School of Public Health and the University of North Carolina School of Medicine in Chapel Hill, North Carolina, have found that dipeptidyl-peptidase-4 (DPP-4) inhibitors do not increase the short-term risk of developing pancreatic cancer.
Researchers identified patients that had taken DPP-4 inhibitors, as well as sulfonylureas (SUs) and thiazolidinediones (TZDs), three classes of medications used to treat type 2 diabetes. Then, researchers compared the rates of developing pancreatic cancer and found no increased risk among those that took DPP-4 inhibitors compared with those that took SUs or TZDs.
DPP-4 inhibitors, which include commonly used medications like sitagliptan, saxagliptan, and linagliptan, work by increasing incretin levels, resulting in decreased glucagon release, increased insulin secretion, decreased gastric emptying, and decreased glucose levels. In 2013, a study found that DPP-4 inhibitors caused changes to the pancreases of rats that may lead to pancreatic cancer. Though this new study was short, researchers say that it should reassure older patients that DPP-4 inhibitors are safe to treat their diabetes.
DPP-4 inhibitors do not increase the short-term risk of developing pancreatic cancer.
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
"Our research shows that short-term use of DPP-4 inhibitors in older diabetes patients does not increase their risk for pancreatic cancer," said John Buse, MD, PhD, director of the Diabetes Care Center at UNC and co-author of the paper in the current issue of the journal Diabetes, Obesity and Metabolism. "However, we just cannot address the long-term safety, yet. There are just not enough people who have taken the drug for many years."
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol